Skip to content

New Smokeless Moxibustion for Knee Osteoarthritis: Study Protocol for A Multicenter, single-Blind, Randomized Controlled Trial

New Smokeless Moxibustion for Knee Osteoarthritis: Study Protocol for A Multicenter, single-Blind, Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200005754
Enrollment
Unknown
Registered
2022-03-22
Start date
2022-04-04
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee osteoarthritis

Interventions

New smokeless Moxibustion:New smokeless Moxibustion
Traditional Moxibustion:Traditional Moxibustion

Sponsors

Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria 1.Age 40 to 75 years. 2.According to the diagnostic criteria of knee osteoarthritis of American rheumatology society 3.Radiographic confirmation of knee osteoarthritis (Kallgren Lawrence grade = 1) 4.Moderate or more severe knee pain for most of the past month; the subjects visual analog scale baseline score for arthritic pain is 40 points and above. 5.Agree to accept the random assignment, understand and be willing to sign the informed consent form.

Exclusion criteria

Exclusion criteria: Exclusion criteria: 1.Knee pain caused by other diseases such as rheumatoid arthritis, fibromyalgia syndrome, chronic fatigue syndrome and ankylosing spondylitis. 2.Received steroids in the past 3 months. 3.Received acupuncture treatment within 3 months. 4.Hyaluronate was injected into the joints in the past 6 months. 5.History of joint puncture or arthroscopy in the past year. 6.History of the knee/hip replacement surgery or planning to perform such surgery during the trial. 7.Use of other topical treatments, such as topical use of drugs. 8.Presence of any serious diseases including heart disease, lung disease, kidney disease, liver disease or malignant tumor, systemic infection or infectious disease and mental illness. 9.Participation in another clinical study in the past 1 month.

Design outcomes

Primary

MeasureTime frame
WOMAC;

Secondary

MeasureTime frame
VAS;SF-36;

Countries

China

Contacts

Public ContactShen Xueyong

Acupuncture &Tuina School, Shanghai University of Traditional Chinese Medicine

sxy1@shutcm.edu.cn021-51322171

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026